

No. 06/BC-HĐQT-IMP

Cao Lanh City, April 03rd, 2023**REPORT**
On Operating Expenses of the Board of Directors and
the Supervisory Board in 2022.

To the attention of: The General Meeting of Shareholders 2023.

Pursuant to Articles 25 and Clause 4, Article 33 of Imexpharm Corporation's Charter;
Based on the audited financial statements of 2022;

The Board of Directors would like to report the operating expenses of the Board of Directors and the Supervisory Board in 2022 and the use the bonuses for extraordinary performance as follows:

1. Remuneration of the Board of Directors and the Supervisory Board

- Unused funds brought forward from last year: VND 3,372,698,528
- Funds taken from gross profit (2%): VND 5,947,023,315
- Payment outturn in 2022: VND 6,482,000,000
- Unused funds brought forward to 2023: VND 2,837,721,843

2. Bonuses for the Board of Directors & Supervisory Board used during the year

- Unused bonuses brought forward from last year: VND 302,377
- Bonus taken from 2022 profits: VND 0
- Bonuses spent in 2022: VND 0
- Unused funds brought forward to 2023: VND 302,377

Sincerely. *pal***Recipients:**

- As above
- Filing: Admin

**ON BEHALF OF BOARD OF DIRECTORS
CHAIRMAN***Nguyễn Quốc Đình*
NGUYEN QUOC DINH